louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02397551: Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day
Official title: Supplementing the Luteal Phase With Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Nile Ivf Center, Cairo, Egypt
name: Adam International Hospital
First posted: 2015-03-25
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 37
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To salvage the luteal phase and improve pregnancy rate in antagonist IVF/ICSI cycles triggered with GnRH agonist. Two strategies are compared supplementing the luteal phase with three small doses (500 IU) of HCG and giving a booster dose of HCG (1500 IU) on the day of ovum pickup.


Eligibility criteria: Inclusion Criteria:

* High responder females undergoing antagonist protocol IVF/ICSI cycle
* More than 14 MII oocytes
* Estradiol more than 3500 pg/ml on day of trigger

Exclusion Criteria:

* Any other protocol
* Normal or poor responders

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 1 year
Secondary outcomes:
measure: OHSS rate
timeFrame: 1 year
Other outcomes:
measure: Chemical pregnancy rate
timeFrame: 1 year
measure: Early miscarriage rate
timeFrame: 1 year
measure: Ongoing pregnancy rate
timeFrame: 1 year
measure: Live birth rate
timeFrame: 1 year
Locations:
city: Cairo
country: Egypt
facility: IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)
city: Giza
country: Egypt
facility: Adam International hospital
city: Giza
country: Egypt
facility: Nile IVF center
Study officials:
affiliation: Cairo University
name: Sarwat Ahwany, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04627051: Atherectomy and Drug Coated Balloon for the Treatment of Arterio-Venous Graft Stenosis
Official title: A Prospective, Single-Centre Study Investigating the Clinical Use and Safety of the Jetstream Atherectomy With Drug Coated Balloon (Ranger) for the Treatment of Dysfunctional Arterio-Venous Graft Stenosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dysfunctional Arterial-venous Grafts
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2020-11-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Treatment of Jetstream™ atherectomy device and Ranger ™ drug coated balloons
Primary purpose: TREATMENT

Brief summary: This single-centre, single-arm, prospective study will enroll 30 subjects presenting with clinical and hemodynamic abnormalities in arteriovenous graft (AVG) in the arm. Subjects will be treated with the Jetstream™ atherectomy device and Ranger™ Drug Coated Balloons (DCB). Subjects will be followed up clinically via office visit or phone visit at 6 and 12 months post procedure. This study is to demonstrate safety and assess the clinical use and outcomes of the Jetstream ™atherectomy device and Ranger™ DCB for the treatment of dysfunctional AV graft.


Eligibility criteria: Inclusion Criteria:

* Male or non-pregnant, non-breastfeeding female ≥18 years of age;
* Subject is willing to provide informed consent, and is willing to comply with the protocol-required follow up visits;
* Target lesion must be a mature arteriovenous graft presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines;
* Subject has a target lesion at the venous anastomosis of the AVG;
* Successful crossing of the stenosis;
* Each lesion length is ≤20mm, which may include tandem lesions that are ≤20mm apart

Exclusion Criteria:

* Subject is currently participating in an investigational drug or device study which has not yet reached its primary endpoint or was previously enrolled into this study;
* Subject has a non-controllable allergy to contrast;
* Subject has more than 3 lesions in the access circuit requiring intervention;
* Target lesion diameter \>10mm;
* A thrombosed access or an access with a thrombosis treated ≤30 days prior to the index procedure;
* Prior surgical interventions of the access site ≤30 days before the index procedure;
* Target lesion is located within a bare metal or covered stent.

Primary outcomes:
measure: Target Lesion Primary Patency (TLPP) through 6 months
timeFrame: within 6 months post intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network
state: Ontario
Study officials:
References:
Clinical trial NCT06957951: Effectiveness of WBV-Supported Core Training on Lumbar Disc Herniation
Official title: Effectiveness of WBV-Supported Core Training on Pain, Function, and Sleep in Lumbar Disc Herniation: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lumbar Disc Herniation
Low Back Pain
Keywords: Whole-Body Vibration
Core Stabilization Exercises
Low Back Pain
Sleep Quality
Functional Disability
Lead sponsor: Gazi University
Sponsor class: OTHER
Collaborators: name: Erzurum Technical University
name: Ataturk University
First posted: 2025-05-06
Enrollment: 45
Sex: MALE
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: TREATMENT

Brief summary: "This randomized controlled trial investigated the effects of conventional physiotherapy, core stabilization exercises, and WBV-supported core stabilization exercises on pain intensity, functional disability, quality of life, and sleep quality in male patients with lumbar disc herniation without neurological deficits."

Detailed description: "This study aimed to compare the effects of whole-body vibration (WBV)-supported core exercises, standard core exercises, and conventional physiotherapy on pain, disability, quality of life, and sleep quality among male patients aged 30-50 years with lumbar disc herniation without neurological deficits. Participants were randomly allocated to one of three groups and underwent 12 sessions over 4 weeks. The outcomes assessed were pain (VAS), disability (ODI), quality of life (SF-36), and sleep quality (PSQI)."

Eligibility criteria: Inclusion Criteria:

* • Male gender

  * Age between 30 and 50 years
  * Diagnosis of lumbar disc herniation (L4-L5 or L5-S1)
  * No neurological deficits

Exclusion Criteria:

* • Prior lumbar surgery

  * Severe cardiopulmonary or musculoskeletal disorders
  * Uncontrolled systemic diseases
  * Participation in another clinical trial

Primary outcomes:
measure: Pain Intensity (VAS)
timeFrame: 4 weeks
measure: Functional Disability (ODI)
timeFrame: 4 weeks
measure: Quality of Life (SF-36)
timeFrame: 4 weeks
measure: Sleep Quality (PSQI)
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Atatürk University Medical Faculty Physical Medicine and Rehabilitation Unit
Study officials:
References:
Clinical trial NCT00004451: Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Keywords: Parkinson disease
neurologic and psychiatric disorders
rare disease
Lead sponsor: National Institute of Mental Health (NIMH)
Sponsor class: NIH
Collaborators: name: University of Virginia
First posted: 1999-10-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: This study will determine whether glucose facilitates memory in healthy elderly people and those with Parkinson's disease.

Detailed description: Subjects fast for 8 hours before receiving a test to determine their blood glucose levels. Following this test, subjects are randomized to receive either a glucose or saccharin sweetened drink. A series of memory tests and an additional 3 blood glucose level tests are administered approximately 15 minutes later. A minimum of 1 week afterward, the subjects return and receive the alternate sweetener followed by additional memory tests.

Eligibility criteria: Inclusion Criteria:

* Three groups of subjects are eligible for this study: Healthy young adults between ages 18 and 30; Healthy elderly adults between ages 60 and 90; AND Anyone diagnosed with Parkinson's disease

Exclusion Criteria:

* Prior surgery to remove part of the stomach
* Diabetes, Addison's, or Cushing's diseases

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: University of Virginia
name: Carol A. Manning
role: STUDY_CHAIR
References:
Clinical trial NCT01510951: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
Official title: A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Moderate to Severe Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Psoriasis
Keywords: AMGEN
PSORIASIS
SAFETY
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2012-01-18
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess the safety, tolerability, immunogenicity, and clinical effects of AMG 811 following single subcutaneous dose administration in subjects with moderate to severe psoriasis.


Eligibility criteria: Inclusion Criteria:

* 18 - 55 years old inclusive at Screening
* Active but clinically stable, plaque psoriasis
* Psoriasis involving ≥ 10% of the body surface area
* A minimum PASI score of ≥ 10 obtained during the screening period
* Additional inclusion criteria apply

Exclusion Criteria:

* Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit
* Evidence of skin conditions other than psoriasis (eg, eczema) at the time of the screening visit or between the screening visit and study drug initiation that would interfere with evaluations of the effect of investigational product on psoriasis
* Any condition that, in the judgment of the investigator, might cause this study to be detrimental to the subject
* Additional exclusion criteria apply

Primary outcomes:
measure: Evaluate the number of adverse events per subject, including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 811
timeFrame: 16 weeks
Secondary outcomes:
measure: Evaluate the efficacy of AMG 811 as measured by the following: the proportion of subjects with a PASI 50, 75 and 90
timeFrame: 16 weeks
measure: Measure the area under the serum concentration curve versus time of AMG 811 after a single dose administration in subjects with moderate to severe psoriasis
timeFrame: 16 weeks
measure: Measure the peak serum concentration (Cmax) of AMG 811 after a single dose administration in subjects with moderate to severe psoriasis
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Herston
country: Australia
facility: Research Site
state: Queensland
city: Nedlands
country: Australia
facility: Research Site
state: Western Australia
city: Christchurch
country: New Zealand
facility: Research Site
city: Grafton, Auckland
country: New Zealand
facility: Research Site
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01663051: Evaluation of the Zilver® Vena™ Venous Stent
Official title: Evaluation of the Zilver® Vena™ Venous Stent
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iliofemoral Venous Outflow Obstruction
Lead sponsor: Cook Group Incorporated
Sponsor class: INDUSTRY
First posted: 2012-08-13
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with symptomatic iliofemoral venous outflow obstruction.

Brief summary: This prospective, non-randomized, multi-center study is intended to evaluate the Zilver® Vena™ stent in the treatment of symptomatic iliofemoral venous outflow obstruction.


Eligibility criteria: Inclusion Criteria:

* Symptomatic venous outflow obstruction in up to two iliofemoral venous segments (one in each limb), demonstrated by:
* CEAP 'C' ≥ 3, or
* VCSS pain score ≥ 2

Exclusion Criteria:

* \< 18 years of age
* Pregnant or planning to become pregnant in the next 12 months
* Planned surgical or interventional procedures (except thrombolysis and thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in patients at high risk for pulmonary embolism) within 30 days prior to or after the study procedure.
* Lesions with intended treatment lengths extending into the inferior vena cava or below the level of the lesser trochanter
* Previous stenting of the target vessel
* Iliofemoral venous segment unsuitable for treatment with available sizes of study devices

Primary outcomes:
measure: Major Adverse Events
timeFrame: 1 month
measure: Patency
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Arnsberg
country: Germany
facility: Klinikum Arnsberg GmbH
city: Galway
country: Ireland
facility: Galway University Hospitals
city: Madrid
country: Spain
facility: Hospital Madrid Monteprincipe
city: Winterthur
country: Switzerland
facility: Kantonsspital Winterthur
city: London
country: United Kingdom
facility: Guy's and St Thomas' Hospital
Study officials:
References:
citation: O'Sullivan GJ, Waldron D, Mannion E, Keane M, Donnellan PP. Thrombolysis and iliofemoral vein stent placement in cancer patients with lower extremity swelling attributed to lymphedema. J Vasc Interv Radiol. 2015 Jan;26(1):39-45. doi: 10.1016/j.jvir.2014.10.010.
citation: O'Sullivan GJ, Sheehan J, Lohan D, McCann-Brown JA. Iliofemoral venous stenting extending into the femoral region: initial clinical experience with the purpose-designed Zilver Vena stent. J Cardiovasc Surg (Torino). 2013 Apr;54(2):255-61.
Clinical trial NCT04809051: Don't Throw Your Heart Away: Patient Study 4
Official title: Don't Throw Your Heart Away: Patient Study 4
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Transplant Disorder
Keywords: Heart Transplant
Transplant Survival
Applied Ethics
Medical Student
Human Behavior
Decision Psychology
Lead sponsor: Carnegie Mellon University
Sponsor class: OTHER
First posted: 2021-03-22
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This empirical study tests whether transplant center performance data that reflect center donor acceptance rates influence patients and their family members to evaluate centers with high organ decline rates less favorably than centers with low organ decline rates. 400 transplant patients and family members will be recruited from transplant support group social media websites and randomized to one of four different information presentation conditions. Upon viewing a pair of outcome tables corresponding to their condition, the participants are asked to choose which hospital is higher performing (one hospital with a non-selective "accepting" strategy and one hospital with a more selective "cherrypicking" strategy.


Eligibility criteria: Inclusion Criteria:

Participants will be asked to participate if they confirm the following inclusion criteria in the consent form.

1. 18 years of age or older
2. must read and understand the information in the consent form
3. must want to participate in the research and continue with the survey
4. must be a pre- or post-transplant patient or family member of the transplant patient

Exclusion Criteria:

Participants who do not meet the primary criterion of being a pre- or post-transplant patient or family member of the transplant patient.

Primary outcomes:
measure: Hospital Choice
timeFrame: 1 day
Secondary outcomes:
measure: Mediator of Hospital Choice
timeFrame: 1 day
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Carnegie Mellon University
state: Pennsylvania
Study officials:
affiliation: Carnegie Mellon University
name: Alison E Butler, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00004351: Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Williams Syndrome
Angelman Syndrome
Prader-Willi Syndrome
Shprintzen Syndrome
Smith-Magenis Syndrome
DiGeorge Syndrome
Chromosome Abnormalities
Keywords: Angelman syndrome
DiGeorge syndrome
Prader-Willi syndrome
Shprintzen syndrome
Smith-Magenis syndrome
Williams syndrome
genetic diseases and dysmorphic syndromes
neurologic and psychiatric disorders
rare disease
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: Baylor College of Medicine
First posted: 1999-10-19
Enrollment: 20
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: OBJECTIVES: I. Investigate phenotype and genotype correlations in patients with Smith-Magenis syndrome (SMS) associated with del(17p11.2).

II. Clinically evaluate SMS patients with unusual deletions or duplication of proximal 17p.

III. Clinically evaluate patients with Williams syndrome with molecular characterization of 7q11.23.

IV. Perform clinical studies of Prader-Willi, Angelman, DiGeorge, and Shprintzen syndrome patients with unique molecular findings in 15q11q13 or 22q11.2.

V. Perform genotype and phenotype correlations in Prader-Willi patients, particularly those with loss of expression of only some of the imprinted transcripts in 15q11-q13.

VI. Evaluate putative Angelman syndrome patients who do not have classic large deletion, uniparental disomy, or imprinting mutations, and perform molecular studies of the Angelman gene, UBE3A, and identify mutations of this gene.

VII. Investigate phenotype and genotype correlations in patients with terminal deletions of chromosome 1p.

Detailed description: PROTOCOL OUTLINE: Patients undergo clinical, cytogenetic, and molecular studies. These include radiographic, neurologic, developmental, and 24 hour sleep studies, ophthalmologic, otolaryngologic, speech and language, and audiologic exams, echocardiogram, and renal ultrasound.

Smith-Magenis patients are also evaluated with the following: urine melatonin levels during day and night hours; anthropometrics; sleep and behavioral history; and renal, immunologic, and cholesterol studies. A clinical and phenotypic map is constructed.

When appropriate, parental chromosome analysis is performed.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Contiguous gene deletion syndrome, e.g.: Smith-Magenis syndrome Williams syndrome DiGeorge syndrome Shprintzen syndrome (velo-cardio-facial syndrome) Prader-Willi syndrome Angelman syndrome Deletion of chromosome 1p Patient age: Any age

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
Study officials:
affiliation: Baylor College of Medicine
name: James R. Lupski
role: STUDY_CHAIR
References:
Clinical trial NCT05745051: The Safety and Effectiveness of CVA-FLOW Software Device for Acute Ischemic Stroke
Official title: A Single-center, Clinical Trial to Evaluate the Safety and Effectiveness of CVA-FLOW Software Device for Acute Ischemic Stroke
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Stroke, Acute
Stroke, Ischemic
Stroke, Cardiovascular
Stroke Hemorrhagic
Lead sponsor: Cvaid Medical
Sponsor class: INDUSTRY
First posted: 2023-02-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to demonstrate the effectiveness and safety of CVA-FLOW, a digital health AI based Telestroke system developed by CVAID Ltd. Company aims to assist certified medical staff to triage acute ischemic stroke patients using dedicated algorithms in order to support application for market approval for CVA-FLOW device.


Eligibility criteria: Inclusion Criteria:

* Suspected hyper-acute stroke patient at the ED, prior to treatment (tPA or EVT)
* Age≥18

Exclusion Criteria:

* Intubated patients upon arrival
* Time from stroke symptoms onset \> 24h
* Patients post treatment (tPA of EVT)
* Patient in acute psychosis state
* Patients who do not speak Hebrew as their mother tongue

Primary outcomes:
measure: Sensitivity and specificity of stroke severity classification by CVA-CORE algorithm
timeFrame: At admission
measure: Sensitivity and specificity of stroke severity classification by CVA-CORE algorithm
timeFrame: after 24 hours
Secondary outcomes:
measure: Device operational performance
timeFrame: At admission
measure: Device operational performance
timeFrame: after 24 hours
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
References:
Clinical trial NCT01010451: Antimicrobial Pulpotomy of Primary Molars
Official title: Survival of Primary Molars Treated With Antimicrobial Pulpotomy or Calcium Hydroxide Pulpectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Inflammation
Necrosis
Keywords: pulpotomy
pulpectomy
primary teeth
dental care for children
Lead sponsor: Universidade Federal de Goias
Sponsor class: OTHER
First posted: 2009-11-10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is a lack of evidence of the long-term successful outcomes of antimicrobial endodontic treatment for primary teeth. This study intended to evaluate (by survival analysis) the effectiveness of an antimicrobial pulpotomy (chloramphenicol, tetracycline, zinc oxide/eugenol) in primary molars compared to calcium hydroxide pulpectomy, testing the hypothesis that antimicrobial pulpotomy could be an alternative pulp therapy for primary teeth with pulp inflammation or necrosis.


Eligibility criteria: Inclusion Criteria:

* Healthy children (ASA PS 1)
* Children presenting one or more primary molar with pulp inflammation or necrosis due to carious lesion and indicated for endodontic therapy

Exclusion Criteria:

* Lost to follow-up

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Goiânia
country: Brazil
facility: Dental School
state: Goiás
Study officials:
References: